Patent Application
20250065014
The present invention relates to a bone repair material useful in the repair of bone defects. The invention further relates to malleable, non-settable, biocompatible bone repair materials that can be used for repair of bone defects.
Every year, more than two million bone graft procedures are performed globally to address bone fractures and other orthopaedic-related injuries resulting from a variety of surgical, degenerative and traumatic causes. The repair of bone defects can be facilitated by placing a bone repair material in the defect site, where a loss of natural bone has occurred or where bone repair is impaired. The bone repair material is meant to selectively and over a sustained period of time promote the regeneration of natural bone structures.
The current clinical gold standard of treatment is autologous bone, harvested primarily from the patient's iliac crest or other locations such as the distal femur, proximal tibia, ribs, and intramedullary canal. Autologous bone provides an osteoconductive three-dimensional scaffold for bone growth, osteogenic cells and osteoinductive growth factors. Despite its immunocompatibility and excellent osteoconductive as well as osteoinductive properties, autograft bone is of limited supply and is often associated with limitations such as the need for additional surgery, pain at the donor site, morbidity, and a high and unpredictable resorption.
Alternatives are naturally derived bone repair materials, produced from cadaver bone. Naturally derived bone repair materials are usually prepared by acid extraction of most of the mineral contents resulting in so-called demineralized bone matrix (DBM). DBM has osteoinductive capabilities by the presence of natural growth factors and osteoconductive properties by the presence of a collagen matrix, the uncertainty of the availability limits its use though.
Another alternative bone repair material is a purely synthetic bone repair material. Synthetic bone repair materials based on hydroxyapatite and/or tricalcium phosphate (TCP) are widely used in oral surgery and orthopaedics. These synthetic bone repair materials are osteoconductive. The lack of osteoinductivity and osteogenic capabilities limit its use in patients with compromised bone regeneration.
To overcome the limitations of naturally derived bone repair materials and the purely synthetic bone repair materials a variety of other artificial or synthetic bone repair material is available on the market typically generally comprising a synthetic component and osteoinductive or osteogenic material such as growth factors.
A variety of growth factors have been shown to induce either cartilage or bone formation in vivo. For example, BMP-2 has been found to be feasible for use in the treatment of fractures and for use in bone regeneration. Certain recombinant osteogenic proteins have also been extensively studied and have demonstrated significant osteogenic activity in several models of bone formation.
It is now known that the production method of recombinant proteins is expensive and thus that bone repair products that comprise such recombinant factors are too costly.
It is further known that the combination products comprising a synthetic component and a growth factor has safety issues. Since recombinant growth factors used are generally single or a very limited type of growth factors in contrast to the whole spectrum of growth factors and proteins that naturally occur in bone overdosing of such specific factors often happens, a phenomenon associated with uncontrollable bone growth can occur.
Injectable and mouldable forms of bone substitute or repair material have been developed as they offer many advantages including increased handling ability during surgery and due to their ability to completely fill contained defects of complex geometric shapes. These bone substitutes currently mostly consist of a polymeric carrier, in which the polymeric carries prevents the cells to infiltrate into the bone defect.
Since bone tissues undergo constant tissue repair regulated by the mineral resorbing cells (osteoclasts) and mineral-producing cells (osteoblasts), the balance between osteoinductive factors such as those present in DBM and minerals and in particular calcium phosphate (CaP) is important in providing all building blocks for bone repair.
Thus, there is a continued need for alternative bone repair materials, that are effective, efficient and safe by design.
The malleable bone repair material of the present invention meets the needs in the art by providing a material that is easy to handle and store, does not settle over time, displays both osteoconductive and osteoinductive properties, is free of polymeric carriers, is substantially bioabsorbable, and is safe by design. The bone repair material is provided as a malleable material consisting of a malleable demineralized bone matrix enriched with an osteoconductive material. The bone repair material may be delivered to a surgeon in a pre-loaded packaging, ready for use.
It has now been discovered by the inventors that a biological component rich in bioactive material and stabilized with an osteoconductive component provides for a malleable bone repair material for use in the treatment of bone defects.
The invention thus pertains to a malleable bone repair material suitable for bone defect repair, wherein the bone repair material composition consists of a biological component comprising bioactive material, preferably a malleable demineralized bone matrix that is enriched with an osteoconductive material. The malleable bone repair material provides for a biodegradable and stable composition with a biological component comprising bioactive material supplemented with the minerals essential for bone healing and growth, wherein the malleable bone repair material comprises a) between 40 and 90 wt % of a biological component based on the total weight of the bone repair material, b) between 5 and 60 wt % of an osteoconductive component, preferably osteoconductive particles by weight of the total bone repair material and, c) optionally between 0.1 and 5 wt % of further osteoactive and/or stabilizing components.
The present invention will be discussed in more detail below, with reference to the attached drawing:
The term “malleable” as used in the context of the invention means that the material is capable of being converted from a first shape to a second shape by the application of pressure. The malleable bone repair material is configured to get any desired shape to fit a bone defect site. In some embodiments, the malleable material may be moulded (such as but not limited to being shaped by hand) to fit into a surgical site, such as a bone defect site. In some embodiments, the malleable material can be injected through a syringe directly into the target tissue site (e.g., bone defect, fracture, or void) into a wide variety of configurations. The malleable bone repair material according to the invention remains in the form of a paste and does not set i.e. does not become hard(er) over time and is, owing its malleable characteristics well bioresorbable.
As used herein, “long bone” refers to hard, dense bones that provide strength, structure, and mobility. A long bone has a shaft and two ends. Long bones typically are longer than they are wide. Examples of long bones include the femur, fibula, humerus, and tibia.
As used herein, “osteoconductive” or “mediates osteoconduction” refers to a scaffold property of a bone graft allowing for the ingrowth of neovasculature and the migration of osteoprogenitors into the graft site.
As used herein, “osteoinductive” or refers to the ability of the bone repair material to induce cell migration, proliferation, and/or differentiation of stem cells, osteoprogenitor cells, osteoblasts or osteocytes into mature bone cells. This process is mediated by bone growth factors or osteoinductive growth factors within the graft material.
As used herein, “bone growth factor” or “osteoinductive growth factor” refers to a growth factor or other proteins that supports osteoinduction. Examples of such growth factors include, but are not limited to, bone morphogenic proteins (e.g. BMP-2, -4, -6, -7 or -9), basic fibroblast growth factor (bFGF), insulin-like growth factor-I and -II (IGF-I and IGF-II), platelet derived growth factor (PDGF) and transforming growth factor-betas (TGF-Ps).
As used herein, a “bone disease, disorder, defect or injury” refers to any bone condition in a subject resulting from cause or condition including, but not limited to, infections, acquired conditions, genetic conditions, or trauma. A disease, disorder, defect or injury of interest herein include any in need of bone growth and/or remodelling.
As used herein, the term “subject” refers to an animal, including a mammal, such as a human being.
The term “stabilizing compound” as used herein indicates a compound that provides improved cohesive characteristics, prevents drying out of the bone repair material over time, contains the moisture content and maintains the handability or manipulatability of the bone repair material over time. Stabilizing compounds according to the invention maintain the handling performance of the bone repair material performance and/or provide the bone repair material with a putty like consistency that is non runny and not sticky. Non limiting examples of such stabilizing compounds are hyaluronic acid, gelatin and glycerine.
In a first aspect, the invention pertains to a bone repair material comprising a biological component enriched with an osteoconductive component.
The biological component according to the invention comprises a solution of a bioactive material, which generally includes at least osteoinductive proteins such as, but not limited to, growth factors and/or a mixture of bioactive factors such as collagen extracted from bone, preferably from demineralized bone matrix. In the context of the invention said biological component of demineralized bone matrix is preferably malleable demineralized bone matrix.
The osteoconductive component in the bone repair material according to the invention is comprising essentially particles. In a preferred embodiment particles of the osteoconductive component have a diameter between 10 nm to 1000 μm.
The malleable bone repair material preferably comprises between a) 40 and 90 wt % of a biological component based on the total weight of the bone repair material, b) between 5 and 60 wt % of an osteoconductive component, preferably osteoconductive particles by weight of the total bone repair material and, c) optionally between 0.1 and 5 wt % of further osteoactive components. In some embodiments the malleable bone repair material consists of between a) 40 and 90 wt % of a biological component based on the total weight of the bone repair material, b) between 5 and 60 wt % of an osteoconductive component, preferably osteoconductive particles by weight of the total bone repair material and, c) optionally between 0.1 and 5 wt % of further osteoactive and/or stabilizing components.
The malleable bone repair material according to the invention is a shelf-stable bone repair material that remains malleable for at least 3 months, preferably at least 6 months, more preferably at least 12 months. In a preferred aspect the malleable bone repair material is shelf stable for at least 3 months, preferably at least 6 months, more preferably at least 12 months when stored at a temperature between about 1 to 10° C., preferably between about 2 to 8° C.
The malleable bone repair material was found to be malleable yet cohesive while not setting or curing over time. In a preferred embodiment the malleable bone repair material has a toothpaste to clay-like viscosity and keeps this viscosity over time. In a preferred embodiment the malleable bone repair material has and keeps a viscosity of about 70 mPa·s to about 400 Pa·s, and preferably, from 140 mPa·s to 300 Pa·s, and most preferably, from 600 mPa·s to 200 Pa·s, taken at 20° C. at a rotation speed of 20 revolutions per minute with a Brookfield Viscometer, Spindle No. 5. In the context of the invention, it is understood that the malleable bone repair material is shelf-stable and thus maintains a stable viscosity over time.
The biological component in the bone repair substrate of the invention comprises a bioactive material.
In one embodiment the bioactive materials for use in the bone repair substrate generally include human growth factors and collagen. In an embodiment the bioactive materials for use in the bone repair substrate are derived from allogeneic or xenogeneic bone, in a particularly preferred embodiment derived from demineralized bone matrix, preferably human demineralized bone matrix. In the context of the invention demineralized bone matrix in aqueous solution is considered malleable demineralized bone matrix.
Malleable demineralized bone matrix is demineralized bone matrix in a form that is capable of being converted from a first shape to a second shape by the application of pressure, such as, for example, in the form of a putty.
The presence of DBM is known to induce cellular recruitment to a site of injury where the recruited cells may eventually differentiate into bone forming cells Such recruitment of cells leads to an increase in the rate of healing and, therefore, to faster recovery for the patient.
It is believed that demineralized bone matrix provides for all factors to initiate, sustain as well as when needed inhibit bone growth.
The bioactive materials for use in the bone repair material and derived from allogeneic or xenogeneic bone are obtainable through methods as described herein and in the art in accordance with U.S. Pat. No. 5,236,456. In an embodiment the bioactive material for use in the bone repair substrate may also comprise a mixture of bone derived bioactive materials and recombinant bioactive materials.
Demineralized bone matrix as used herein, refers to any material obtainable by removing mineral material from bone tissue according to conventional tissue bank techniques as described in Reddi et al. “Biochemical sequences in the transformation of normal fibroblasts in adolescent rats”, Proc. Nat. Acad. Sci, 69 pp 1601-5 (1972), Zhang et al. “Effect(s) of the Demineralization Process on the Osteoinductivity of Demineralized Bone Matrix” Journal of Periodontology, Volume 68, Issue 11 (1997) and according to U.S. Pat. No. 6,189,537 and according to U.S. Pat. No. 7,811,608. In a preferred embodiment, the demineralized bone matrix described herein include preparations containing less than 8% calcium and preferably not less than approximately 2% calcium by weight. Bioactive material, preferably demineralized bone matrix as used in the malleable bone repair material preferably has a calcium-content between 1 and 10 wt %, preferably between 2 and 8 wt % based on total weight of the demineralized bone matrix.
The bioactive material from bone may be provided in any suitable manner known in the art. Demineralized bone matrix products may serve as a source for extraction of bioactive material, which are also available commercially, including for instance, from AlloSource (Denver, CO, USA), KeraLink (Baltimore, Maryland), and others. The bone source may be selected from cortical, cancellous, or corticocancellous bone. Further the bone may be of allogeneic or xenogeneic origin, in a preferred embodiment the origin of the bone is human bone. Use of bioactive material from bone in tissue repair compositions is described in the art such as U.S. Pat. Nos. 4,394,370, 5,405,390, 5,236,456 as well as WO2021005412 A1.
In a preferred embodiment the bioactive material is malleable demineralized bone matrix that may be extracted from demineralized bone matrix having a fiber and/or particle size smaller than about 1000 μm, more preferably smaller than about 900 μm, even more preferably smaller than about 850 μm. In a preferred embodiment the malleable bone repair material thus comprises malleable bioactive material derived from a demineralized bone matrix product as a starting material. The bioactive material essentially consists of material derived from demineralized bone matrix and is preferably in the form of a gel or putty comprising DBM-derived collagen and proteins. The bioactive materials in such a gel or putty are understood to no longer have a size range smaller than about 1000 μm yet are reduced to the molecular size ranges of the composition.
Bioactive material derived from allogeneic or xenogeneic bone, in particular bioactive material derived from demineralized bone matrix comprises a selection or all of the following factors: non-collagenous proteins including phosphoproteins, osteocalcin, matrix Gla protein; osteoinductive growth factors including bone morphogenic proteins (BMP) such as BMP-2, BMP-4, BMP-6 and BMP-7; factors that contribute to bone growth such as fibroblast growth factor-2 (FGF-2), insulin like growth factor-I and II (IGF-I and IGF-II), platelet derived growth factor (PDGF), and transforming growth factor beta-1 (TGF-beta 1) and further type I collagen and traces of calcium.
In a preferred embodiment the singular bioactive factors of the malleable demineralized bone matrix have a beneficially small size distribution, between 3 kDa and 800 kDa, more preferably between 3.2 and 700 kDa, even more preferably between 3.5 and 600 kDa.
In an embodiment some of the malleable demineralized bone matrix may be in an agglomerated state having a size of at most 850 μm.
Not only osteoinductive growth factors play an important role in bone remodelling. The regulation of osteoclasts that provide for bone growth inhibition is important for controlled bone formation. E3 ubiquitin ligases such as Smurf1, β-TrCP1, WWP1, and related adapter proteins (e.g., Schnurri 3) are known to regulate protein activity of RUNX2 or ATF4 by promoting their proteasomal-dependent degradation. (Garrett et al. J Clin Invest. 2003, 111(11): 1771-1782.). Mixtures of such regulating factors are also present in the bioactive material derived from allogeneic or xenogeneic bone, in particular bioactive material derived from demineralized bone matrix.
The bioactive material comprises the whole spectrum of naturally derived proteins, which results in a controlled and physiological bone remodelling.
In a most preferred embodiment, the bioactive material comprises osteoinductive and osteoconductive factors derived from allogeneic or xenogeneic bone, in particular from demineralized bone matrix. In a particularly preferred embodiment, the biological material of the biological component is malleable demineralized bone matrix.
The biological component of the bone repair material typically comprises about 3000 to 60000 microgram per gram, preferably 4000 to 50000 microgram per gram, and even more preferably 6000 to 40000 microgram of bioactive material per gram biological component. In a preferred embodiment the biological component of the bone repair material comprises 3000 to 60000 microgram per gram, preferably 4000 to 50000 microgram per gram, and even more preferably 6000 to 40000 microgram of demineralized bone matrix per gram biological component. Alternatively worded, the biological component of the bone repair material comprises about 0.3 to 6 wt %, preferably 0.4 to 5 wt %, even more preferably 0.6 to 4 wt % of bioactive material per gram of biological component, preferably the bioactive material is demineralized bone matrix, most preferably malleable demineralized bone matrix.
The biological component of the bone repair component typically forms between 40 and 90 wt %, preferably between 45 and 87 wt %, more preferably between 50 and 85 wt % of the total weight of the bone repair material. In one aspect of the invention the bone repair material may comprise between 54 and 83 wt % of biological material by weight of the bone repair material.
The osteoconductive component in the bone repair material is generally made of particles. The primary purpose of the osteoconductive component is to mediate osteoconduction. The osteoconductive particles of the osteoconductive component have a composition and architecture appropriate to remain in place and function as a carrier for the biological component. While these characteristics may vary between applications, exemplary compositions of the osteoconductive particles of the malleable bone repair substrate generally include particles comprising a synthetic osteoconductive matrix, such as a calcium phosphate-based matrix, a calcium sulphate-based matrix or bioglass matrix, or a human derived osteoconductive matrix, such as demineralized bone matrix powder, demineralized bone matrix fibers, cancellous bone matrix and bone chips. Essentially, in order for the bone repair material to be, and remain, malleable the osteoconductive particles used in the bone repair material according to the invention do not react with one another in such a way that a setting reaction, wherein the bone repair material would set, takes place.
When the particles of said osteoconductive component are in the form of a calcium phosphate-based matrix, said matrix may be selected from monocalcium phosphate monohydrate, dicalcium phosphate, dicalcium phosphate dehydrate, octocalcium phosphate, precipitated hydroxyapatite, precipitated amorphous calcium phosphate, monocalcium phosphate, alpha-tricalcium phosphate (α-TCP), beta-tricalcium phosphate (β-TCP), sintered hydroxyapatite, oxyapatite, tetracalcium phosphate, hydroxyapatite, calcium-deficient hydroxyapatite, and combinations thereof.
Worded alternatively calcium-phosphate-based particles of the osteoconductive component may comprise monocalcium phosphate monohydrate, dicalcium phosphate, dicalcium phosphate dehydrate, octocalcium phosphate, precipitated hydroxyapatite, precipitated amorphous calcium phosphate, monocalcium phosphate, alpha-tricalcium phosphate (α-TCP), beta-tricalcium phosphate (β-TCP), sintered hydroxyapatite, oxyapatite, tetracalcium phosphate, hydroxyapatite, calcium-deficient hydroxyapatite, or combinations thereof.
In the context of the invention when mixtures of calcium-phosphates are used such combinations preferably do not settle or cure. The use of calcium-phosphates that do not react with each other and set allows for the bone repair material to remain malleable and thereby allow for instant cell penetration in situ and good bone repair properties. Known mixtures or combinations that are not part of combinations that can be used in the osteoconductive component are combinations of calcium phosphates known in the art used to prepare cements such as tetra calcium phosphate in combination with any one of dicalcium phosphate dihydrate, dicalcium phosphate, anhydrous dicalcium phosphate and tricalcium phosphate or β-TCP in combination with any one of anhydrous dicalcium phosphate with calcium carbonate, dicalcium phosphate monohydrate, calcium sulphate or α-TCP in combination with any one of tetracalcium phosphate and dicalcium phosphate dihydrate. Setting properties of combinations of calcium phosphates are known in the art and can also be assessed by the skilled person by admixing combinations of calcium phosphates in the presence of an aqueous medium and assessing whether or not said combination sets.
The osteoconductive component of the malleable bone repair material preferably comprises osteoconductive particles, preferably having a diameter in the nanorange. It is believed that the use of nano-sized particles beneficially improves the cohesiveness and contribute to the stability of the malleable bone repair composition according to the invention. The osteoconductive particles preferably have an average diameter between 10 and 300 nm, preferably between 25 and 250 nm, more preferably between 50 and 150 nm, even more preferably between 75 and 125 nm. In a preferred embodiment at least 65 wt %, preferably at least 70, more preferably at least 75 wt %, more preferably at least 80 wt %, even more preferably at least 90 wt % based on total weight of the osteoconductive particles are in the nanometer size-range. In an aspect of the invention essentially all osteoconductive particles are in the nanometer size-range. In an alternative embodiment the osteoconductive component of the malleable bone repair material may further comprise osteoconductive particles having a diameter in the micrometer size range. In an embodiment at most 35 wt % of the osteoconductive particles are in the micrometer range, preferably at most 30 wt %, more preferably at most 25 wt %, more preferably at most 20 wt %, most preferably at most 15 wt %. In an alternative embodiment the malleable bone repair material may further comprise between 0.01 wt % and 20 wt %, preferably between 0.1 wt % and 15 wt %, more preferably between 0.2 wt % and 10 wt %, more preferably between 0.5 wt % and 8 wt %, most preferably between 1 wt % and 5 wt % of osteoconductive particles having a diameter in the micrometer size range based on the total weight of the osteoconductive particles. The osteoconductive particles in the micrometer range preferably have an average diameter between 20 and 1,000 μm, preferably between 50 and 750 μm, more preferably between 100 and 500 μm. Diameters apply to the largest dimension of the particles. The diameter can be determined by methods known in the art using SEM or sieve analysis according to ISO13175-3.
Since nano-sized osteoconductive particles contribute to the cohesiveness and stability of the malleable bone repair material it is preferred that more than 50%, more preferably more than 75%, even more preferably more than 90%, most preferably essentially all of the total volume of the nano-sized particles is in singular or unagglomerated form. Agglomeration would impair the particles in providing their beneficial effect on the cohesiveness and/or stability of the malleable bone repair material.
The osteoconductive particles are formed according to processes known in the art. The size of the particles is obtained using generally known processes.
The osteoconductive particles forming the osteoconductive component typically form between 5 and 60 wt %, preferably between 10 and 55 wt %, more preferably between 13 and 50 wt % of the total weight of the malleable bone repair material.
In one embodiment there is provided for the presence of particles in the bone repair material in both the nanosized ranged and the microsized range. It is believed that the addition of a mixture of nano- and micrometer sized particles to the bone repair material may provide for more structural integrity of the bone repair material.
In an embodiment of the invention the bone repair material is free of synthetic polymers and/or synthetic fillers, this provides the advantage that the bone repair material is not preventing the cells to penetrate the bone repair material, as is often the case when synthetic polymers are used.
In an embodiment the biological component of the bone repair component forms between 40 and 90 wt %, preferably between 45 and 87 wt %, more preferably between 50 and 85 wt % of the total weight of the bone repair material.
In one embodiment the bone repair material comprises a) between 40 and 90 wt %, preferably between 45 and 87 wt %, more preferably between 50 and 85 wt % of biological component based on the total weight of the bone repair material, b) between 5 and 60 wt %, preferably between 10 and 55 wt %, more preferably between 13 and 50 wt % osteoconductive component, preferably osteoconductive particles by weight of the total bone repair material and, c) optionally between 0.1 and 5 wt %, preferably between 0.2 and 2 wt %, even more preferably between 0.5 and 1 wt % of further osteoactive and/or stabilizing components such as, but not limited to, hyaluronic acid, gelatin and glycerin.
In one embodiment there is provided a syringe containing malleable bone repair material according to the invention.
The bone repair material optionally comprises osteoactive and/or stabilizing components such as, but not limited to hyaluronic acid, glycerine, carboxy methyl cellulose and gelatin. In the context of the invention the optional osteoactive and/or stabilizing component are not osteoconductive particles of the osteoconductive component. In one embodiment these components form between 0.1 and 5 wt %, preferably between 0.2 and 2 wt %, even more preferably between 0.5 and 1 wt % of the bone repair material. The weight percentage of the osteoactive and/or stabilizing components is not included in the weight of the biological component nor the osteoconductive component. It is believed that the addition of hyaluronic acid renders the bone repair material more malleable and prevents dehydration of the bone repair material thereby providing for a longer shelf-life. The addition of the further components in addition to the biological material of the biological component provides for a more viscous bone repair material. The use of (synthetic) polymers such as poloxamers is not advised since it is believed that such molecules inhibit cell penetration into the bone repair material.
It is believed that the bone repair material within these component ranges provides for a versatile bone repair material useful for a wide range of bone defects. In a particular embodiment the bone repair material is particularly suitable for the repair of long bone defects.
In a preferred embodiment the malleable bone repair material of the invention is particularly useful in a wide variety of bone defects ranging from fractures in long bone, so-called non-union long-bone defects to bone defects caused by bone tumours or trauma. The malleable bone repair material is thus of particular use in non-load-bearing applications such as repair of contained bone defects.
The invention also provides for therapeutic methods of treating bone fractures and defects in a mammal, which involve administering to a mammal having such bone fractures or defects a therapeutically effective amount of the bone repair material as described herein.
In one aspect of the invention the malleable bone repair material according to the invention is for therapeutic use in the treatment of bone defects in subjects in need thereof. In an aspect the malleable bone repair material according to the invention is for medical use. In one aspect bone repair material is for use as a medical device.
One aspect of the invention includes use of the bone repair material for the manufacture of a medicament for the treatment of patients suffering from bone defect.
One aspect of the invention includes a method for treating a patient comprising the steps of contacting a bone tissue of the patient with the bone repair material.
In one embodiment the malleable bone repair material provides for an implantable device.
In one embodiment there is provided a malleable bone repair material for use in the treatment of bone defects in a subject in use thereof. There is further provided a malleable bone repair material for use in the treatment of bone defects in a subject in use thereof wherein the bone repair material comprises a) between 40 and 90 wt %, preferably between 45 and 87 wt %, more preferably between 50 and 85 wt % of biological component based on the total weight of the bone repair material, b) between 5 and 60 wt %, preferably between 10 and 55 wt %, more preferably between 13 and 50 wt % osteoconductive component, preferably osteoconductive particles by weight of the total bone repair material and, c) optionally between 0.1 and 5 wt %, preferably between 0.2 and 2 wt %, even more preferably between 0.5 and 1 wt % of further osteoactive components such as, but not limited to, hyaluronic acid, gelatin and glycerin.
The bone repair material may be used to treat or prevent bone loss, promote union, or heal a fracture, and/or otherwise increase bone mass or treat a bone condition in the patient. Additionally, the bone repair material according to the invention facilitates the formation of new bone without impairing the natural healing process. The malleable bone repair material according to the invention beneficially is not a setting material, the malleable bone repair material therewith allows easy infiltration of cellular infiltrates involved in repair of the bone defect.
The present invention has been described above with reference to a number of exemplary embodiments. Modifications and alternative implementations of some parts or elements are possible, and are included in the scope of protection as defined in the appended claims.
Manufacturing Example of Bone Repair Material with Round Shaped Osteoconductive Particles
To prepare round-shaped particles the following steps were performed:
Manufacturing Example of Bone Repair Material with Rice Shaped Osteoconductive Particles
To evaluate the biological incorporation and remodeling into new bony structure of 2 bone repair materials with different Calcium Phosphate Nanoparticle formulas a rabbit study was undertaken Formula 1 was osteoconductive material based on HA (Calcium Nitrate+Ammonium Phosphate according to example 2), formula 2 on HA (Calcium Acetate+Phosphoric Acid according to example 1).
Nine rabbits underwent surgery to create a small round defect in each femoral condyle. The defect of the left femur was filled with material 1 and the defect of the right femur with material 2. After 28 days of follow-up (including weekly X-rays), rabbits were sacrificed, and femoral fragments were harvested and subjected to microCT.
The calcium acetate based formula according to example 1 was judged as performing slightly better than the other formula based on qualitative observation of the μCT images at experimental day 28.
Malleable Bone Repair Material with High Concentration of Biological Component.
To prepare a malleable bone repair material with a high concentration of biological component 100 mg of Demineralized Bone was suspended in 1093 mg water, to achieve 1193 mg of the biological component. 402 mg of nano-sized low crystalline hydroxyapatite particles, to form a malleable bone repair material.
Malleable Bone Repair Material with Medium Concentration of Biological Component.
To prepare a malleable bone repair material with a medium concentration of biological component 25 mg of Demineralized Bone was suspended in 1063 mg water, to achieve 1088 mg of the biological component. 402 mg of nano-sized low crystalline hydroxyapatite particles, to form a malleable DBM.
Malleable Bone Repair Material with a Low Concentration of Biological Component.
To prepare a malleable bone repair material with a low concentration of biological component 3 mg of Demineralized Bone was suspended in 1063 mg water, to achieve 1066 mg of the biological component. 402 mg of nano-sized low crystalline hydroxyapatite particles, to form a malleable DBM.
Formulations of Malleable bone repair material (comprising sheep bone derived protein-based bioactive material, enhanced with osteoconductive Calcium Phosphate nanoparticles according to the invention with three different concentrations of the biological component) was evaluated on biological incorporation, remodelling, and resorption in a critical size defect model in sheep. The Malleable bone repair material was also assessed for its osteoinductive capacity using C2C12 analysis on BMP2.
The aim of this study was to assess biological incorporation, remodelling into new bony structure and resorption of the Malleable DBM (as compared to standard of care).
The experiment was performed with 10 sheep in total, each sheep was exposed to critical size drilled bone defects (6 defects per sheep)
Exemplary defect TD351_31 was filled with about 1 ml of the bone repair material with a high concentration of biological active ingredient. After 8 weeks the area where the defect was located, was analyzed using micro-CT. In
Exemplary defect TD351_13 was filled with about 1 ml of the bone repair material with a medium concentration of biological active ingredient. After 8 weeks the area where the defect was located, was analyzed with micro-CT. In
Exemplary defect TD351_54 was filled with about 1 ml of the bone repair material with a low concentration of biological active ingredient). After 8 weeks the area where the defect was located, was analyzed with micro-CT. In
As a control two further groups of sheep were taken into account. As the positive control a bone defect was filled with autologous bone from the sheep. Exemplary defect TD351_15 was filled with autologous bone. After 8 weeks the area where the defect was located, was analysed with micro-CT. In
As a negative control a bone defect was left unfilled with any material. Exemplary defect TD351_07 was not filled. After 8 weeks the area where the defect was located, was analysed with micro-CT. In
In addition to the in vivo behaviour of the bone repair material ALP induced by BMP-2 was assessed in C2C12 cells by determination of the ALP index (OI) with bone repair material with a high and a medium concentration of bioactive material.
The osteoinductivity of the bone morphogenetic proteins (BMPs), present in the bone repair material, was measured in vitro using a pluripotent myoblast C2C12 cell line by the method described in Han B et al. J. Orthopedic Research, vol 21(4), 2003; pages 648-654. Alkaline phosphatase activity induced by co-incubation of DBM with C2C12 cells was dose-responsive and corresponds to the quantity of active BMPs in DBM.
Based on the results obtained with the in vitro and in vivo correlation studies, a bone repair material with an ALP index of more than 20% (0.20) above a (negative) baseline was considered osteoinductivity positive.
To assess the shelf-life of the malleable bone repair material a batch of malleable bone repair material with high concentration of biological component according to example 4 was prepared. The bone repair material was put into syringes and stored at a temperature of 4-8° C. The malleability of the bone repair material was assessed after storage for 6, 17 and 45 weeks. At all 3 time points the bone repair material could be pushed out of the syringe and moulded manually into a sphere.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2030793 | Jan 2022 | NL | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/NL2023/050042 | 1/31/2023 | WO |
